295 reports of suspected side effects of implants in 2023 In 2023, 295 individuals reported one or more suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI).
Growth of digital healthcare stabilised in 2023 The growth in the use of digital healthcare tools by care providers stabilised in 2023. This was mainly because most care providers were already using particular digital tools in 2022, such as the patient portal – on which patients can view the outcomes of examinations – and e-consultations (digital written contact with doctors).
In 2023 more Dutch people play sports on a weekly basis In 2023, 56% of the Dutch population aged four and over played sports at least once a week. This figure marks an increase from 53% in 2022. Notably, the percentage of individuals with physical disabilities who played sports weekly saw a significant rise, from 23% to 29%.
RIVM identifies three major challenges for public health and healthcare in period to 2050 The Dutch public health and healthcare will face three crucial challenges in the period to 2050. This is according to RIVM’s preview of the Dutch Public Health Foresight Study 2024.
Number of Combined Lifestyle Intervention participants more than doubles in one year The number of participants that has started the Combined Lifestyle Intervention (CLI) has more than doubled over the course of a single year. Nationwide, over 82,000 people have now started the CLI. According to RIVM’s annual report, most of the participants achieve a good outcome.
Adherence to Physical Activity Guidelines particularly low among young adults The number of people in the Netherlands aged four and over who meet the Physical Activity Guidelines has fallen since 2020. In 2022, 44.3% of the population was sufficiently physically active.
Participation rates in cancer population screening programmes continue to decline The number of participants in the population screening programmes for breast cancer, cervical cancer and colorectal cancer continues to decline. This decline has been going on for years, reaching its lowest point in 2020.
Metabolic disorder ALD added to newborn blood spot screening Since 1 October, the metabolic disorder adrenoleukodystrophy (ALD) has been added to the Dutch newborn blood spot screening. From now on, the blood of newborn boys will also be tested for this disorder. ALD in boys can be treated if it is detected in time.
MEBI: 193 reports of suspected side effects of implants in 2022 In 2022, 193 individuals reported suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI). Most reports received concerned breast implants, copper IUDs and wrinkle fillers. This is highlighted in MEBI’s annual report.
From 1 October 2023, heel prick test also screens for metabolic disorder ALD From 1 October 2023, the blood of newborn babies will also be tested for the metabolic disorder adrenoleukodystrophy (ALD). This is done with the heel prick screening test.